Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Welcure Drugs & Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

CEO

Welcure Drugs & Pharmaceuticals CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Altaf Shah	MD, CFO & Director	less than a year	Veri yok	Veri yok
Manowar Ali	Company Secretary	no data	Veri yok	Veri yok
Vishal Mehra	Chairman	2.1yrs	₹35.00k	Veri yok
Suraj Solanki	Additional Non-Executive & Non-Independent Director	less than a year	Veri yok	Veri yok
Deepika Iyer	Non-Executive & Independent Director	less than a year	Veri yok	Veri yok
Ashish Abbi	Non-Executive Independent Director	less than a year	Veri yok	Veri yok

0.9yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: 524661 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.9 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Welcure Drugs & Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Welcure Drugs & Pharmaceuticals Limited Informs Resignation of Ashish Abbi as Non Executive Independent Director

Less than half of directors are independent

Welcure Drugs & Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Welcure Drugs & Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Welcure Drugs & Pharmaceuticals Limited Announces the Resignation of Priti Rajesh Kharwar as Additional Director, Effective from March 28, 2024

High number of new and inexperienced directors

Recent updates

Welcure Drugs & Pharmaceuticals Limited Informs Resignation of Ashish Abbi as Non Executive Independent Director

Less than half of directors are independent

Welcure Drugs & Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Welcure Drugs & Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Welcure Drugs & Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 14, 2024

Welcure Drugs & Pharmaceuticals Limited Approves Shifting of Branch Office of the Company

Welcure Drugs & Pharmaceuticals Limited to Report Q4, 2024 Results on May 28, 2024

New minor risk - Share price stability

Welcure Drugs & Pharmaceuticals Limited Announces the Resignation of Priti Rajesh Kharwar as Additional Director, Effective from March 28, 2024

High number of new and inexperienced directors

Welcure Drugs & Pharmaceuticals Limited Announces Board Resignations

Welcure Drugs & Pharmaceuticals Limited Approves Appointment of Altaf Hussain Shah as Chief Financial Officer

Welcure Drugs & Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

High number of new and inexperienced directors

New major risk - Share price stability

Welcure Drugs & Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 14, 2023

Welcure Drugs & Pharmaceuticals Limited Announces Resignation of Mayank Bhandari as Non Executive and Independent Director

Investor sentiment improves as stock rises 20%

Welcure Drugs & Pharmaceuticals Limited, Annual General Meeting, Sep 28, 2023

Welcure Drugs & Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 14, 2023

Welcure Drugs & Pharmaceuticals Limited to Report Q4, 2023 Results on May 29, 2023

Welcure Drugs & Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 13, 2023

High number of new and inexperienced directors

High number of new directors

Welcure Drugs & Pharmaceuticals Limited Announces Resignation of Sudhir Chandra as Managing Director, with Effect from October 8, 2022

Second quarter 2023 earnings released

Welcure Drugs & Pharmaceuticals Limited to Report Q2, 2023 Results on Oct 08, 2022

Founder & Non Executive Director recently sold ₹2.3m worth of stock

Welcure Drugs & Pharmaceuticals Limited Announces Chief Financial Officer Changes

Welcure Drugs & Pharmaceuticals Limited Announces Resignation of Director

First quarter 2023 earnings released: ₹0.042 loss per share (vs ₹0.02 loss in 1Q 2022)

Welcure Drugs & Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2022

Full year 2022 earnings released: EPS: ₹0.02 (vs ₹0.045 in FY 2021)

Less than half of directors are independent

Full year 2022 earnings released: EPS: ₹0.02 (vs ₹0.045 in FY 2021)

First quarter 2022 earnings released

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹0.05 (vs ₹0.008 loss in FY 2020)

New 90-day low: ₹2.02

Welcure Drugs & Pharmaceuticals Limited to Report Q3, 2021 Results on Jan 16, 2021

New 90-day high: ₹2.10

First half earnings released

Welcure Drugs & Pharmaceuticals Limited Announces Appointment of Gagan Juneja as Additional Independent Director

Welcure Drugs & Pharmaceuticals Limited to Report Q2, 2021 Results on Oct 16, 2020

New 90-day high - ₹1.94

New 90-day high - ₹0.97

CEO

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi